Degradation Mechanisms for Water-Soluble Drugs in Solid Dosage Forms

1969 ◽  
Vol 58 (5) ◽  
pp. 549-553 ◽  
Author(s):  
J.Thurø Carstensen ◽  
Modest Osadca ◽  
S.H. Rubin
2021 ◽  
Vol 28 ◽  
Author(s):  
Phuong H.L. Tran ◽  
Thao T.D. Tran

: Lipid-based formulations have recently been investigated as a promising approach to enhance the bioavailability of drugs, especially poorly water-soluble drugs. The encapsulation of lipid-based formulations in porous materials can result in a transformation of liquids or semisolid forms to solid dosage forms. Moreover, the specific structure of porous carriers could offer an enhanced ability to load and control active pharmaceutical ingredients. Although there have been prominent reports on lipid-based formulations and porous materials as promising technologies for controlled drug release, the overall methods of encapsulating lipid-based formulations need to be discussed for further formulation investigations. This review aims to present the key strategies used for producing porous carriers containing lipid-based formulations. We also discuss methods that enhance the encapsulation efficiency of loaded drugs within porous structures (instead of lipid-based formulations). Moreover, the critical factors that affect tablet formation are outlined. This overview of lipid-based formulations encapsulated within porous materials provides a summary of the technical methods used in the development of these formulations and their clinical translation.


Author(s):  
Manisha Rokade ◽  
Pradnya Khandagale ◽  
Dipti Phadtare

The poor dissolution rate of water-insoluble drugs is still a substantial problem confronting the pharmaceutical industry. There are several methods used to increase the solubility of drugs, of those liquid-solid compact technique is a new and promising addition towards such a novel aim, that the solubility of the insoluble drug moiety is increased by the aid of non-volatile solvents and hence increasing the dissolution and bioavailability. Oral drug administration has been one of the most convenient and widely accepted routes of delivery for most of the therapeutic agents. It is one of the most extensively used routes of drug administration because of its obvious advantages of ease of administration, improved patient compliance, and convenience. The enhancement of oral bioavailability of poorly water-soluble drugs remains one of the most challenging aspects of drug development. A more recent technique, “powdered solution technology” or “Liquisolid technology”, has been applied to prepare water-insoluble drugs into rapid-release solid dosage forms. The limited solubility of drugs is a challenging issue for the industry, during the development of the ideal solid dosage form unit. The technique is based upon the dissolving the insoluble drug in the nonvolatile solvent and admixture of drug loaded solutions with appropriate carrier and coating materials to convert into acceptably flowing and compressible powders.


1980 ◽  
Vol 63 (4) ◽  
pp. 692-695
Author(s):  
Charles C Clark ◽  
◽  
W Brittan ◽  
C Hezeau ◽  
D Hughes ◽  
...  

Abstract Seven laboratories collaboratively studied a method for the quantitative ultraviolet (UV) determination of ephedrine sulfate in solid dosage forms. Ephedrine is separated from water-soluble impurities and strong acids by elution from a weakly basic Celite column, and further cleaned up by retention on a weakly acidic column while the weak acids, weak bases, and organic-soluble neutrals are eluted. Ephedrine is eluted from the column after neutralization with NH3 and is converted to benzaldehyde via an on-column periodate reaction. The samples collaboratively studied consisted of 3 synthetic preparations of known ephedrine sulfate concentrations and 2 commercial preparations containing ephedrine sulfate. One commercial sample was submitted as a blind duplicate. Recoveries for the synthetic preparations averaged 101.7, 101.2, and 100.5% for mixtures containing 7.93, 9.35, and 6.85% ephedrine sulfate, respectively. The means and standard deviations for the commercial preparations were 24.72 ± 0.376 mg/dosage unit for the preparation labeled to contain 25 mg/dosage unit, and 22.46 ± 0.643 and 22.29 ± 0.339 mg/dosage unit for the blind duplicate labeled to contain 24 mg/dosage unit. The method has been adopted as official first action.


2021 ◽  
Vol 598 ◽  
pp. 120361 ◽  
Author(s):  
S. Henry ◽  
A. Samaro ◽  
F.H. Marchesini ◽  
B. Shaqour ◽  
J. Macedo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document